Nucleolin (NCL) is a multifunctional protein predominantly located in the nucleolus, where it plays critical roles in ribosome biogenesis, chromatin organization, and regulation of gene expression. It is also found on the cell surface and within the cytoplasm, participating in diverse cellular processes such as cell proliferation, apoptosis, and stress response. Structurally, NCL contains three distinct domains: an N-terminal acidic region, a central RNA-binding domain, and a C-terminal glycine/arginine-rich domain, enabling interactions with nucleic acids, proteins, and lipids.
NCL antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. In research, these antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect NCL in tissues or cultured cells. Aberrant NCL expression is linked to cancer, viral infections, and neurodegenerative diseases. Overexpression of NCL is observed in many cancers, where it promotes tumor growth, angiogenesis, and metastasis, making it a potential therapeutic target. Additionally, surface-exposed NCL serves as a receptor for pathogens, including viruses and bacteria, highlighting its role in infection mechanisms.
The development of NCL-targeted therapies, such as aptamers or monoclonal antibodies, underscores its clinical relevance. Research using NCL antibodies continues to uncover its complex roles in disease pathways, offering insights for diagnostic and therapeutic innovations.